Your Health, We Care
As a new generation ROS1/NTRK inhibitor, repotrectinib has shown excellent efficacy in the treatment of ROS1+NSCLC.
In the TRIDENT-1 clinical trial, for ROS1+NSCLC patients treated with TKI, the progression free survival (mPFS) of repotrectinib was as long as 35.7 months, which exceeded the survival improvement achieved by previous first-line TKI treatments.
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
